Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04785794 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
A Phase 1 study, sponsored by FluGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
NCT04785794 is a Phase 1 study that has completed, run by FluGen. The registered enrollment target is 122 participants.
The verdict
NCT04785794, a Phase 1 study, has completed, sponsored by FluGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled Phase 1b study to evaluate safety and immunogenicity of the investigational Sing2016 M2SR H3N2 influenza vaccine delivered intranasally to a healthy adult population age 50 to 85 years.
Interventions
- OTHER Placebo
- BIOLOGICAL Sing2016 M2SR H3N2 influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2021-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04785794
The ClinicalTrials.gov registry entry for NCT04785794 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FluGen, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04785794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04785794 about?
NCT04785794 is a clinical study titled "Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old". This is a randomized, double-blind, placebo-controlled Phase 1b study to evaluate safety and immunogenicity of the investigational Sing2016 M2SR H3N2 influenza vaccine delivered intranasally to a healthy adult population age 50 to 85 years.
What is the current status of trial NCT04785794?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2021-06-30. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT04785794?
The interventions under investigation include: Placebo (OTHER), Sing2016 M2SR H3N2 influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04785794?
This trial is sponsored by FluGen, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.